Phase III BELLINI: Updated Results With Venetoclax or Placebo Plus Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

May 29-31, 2020; Online at meetings.asco.org/am
Venetoclax plus bortezomib/dexamethasone was selectively associated with favorable survival outcomes in patients with R/R myeloma and the t(11;14) cytogenetic marker in this updated study analysis.
Format: Microsoft PowerPoint (.ppt)
File Size: 221 KB
Released: June 2, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie Inc.
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm Therapeutics

Related Content

Downloadable slideset on the safety of BTK inhibitors and their management for patients with CLL, from Clinical Care Options (CCO)

George Follows, BM, BCh, PhD Released: June 11, 2021

Downloadable slideset on the combination of BTK inhibitors in frontline CLL, from Clinical Care Options (CCO).

person default Veronique Leblond, MD Released: June 11, 2021

Primary results of tisagenlecleucel in adult patients with R/R follicular lymphoma, from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 11, 2021

Update from FORTE trial with KRd-ASCT vs KRd12 and KR vs R by cytogenetic risk groups from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue